glp 3 rt vs glp 1 glp-3 retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by GLP-3 RT

Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A

The most common source of confusion is mixing up milligrams, milliliters, concentration, and units

Dehydration and reduced oral intake: The appetite-suppressing effects of these medications, combined with gastrointestinal side effects such as nausea and vomiting, can lead to inadequate fluid and electrolyte intake

Injectable GLP-1 medications currently have a stronger and more established evidence base for weight loss, but oral options are showing meaningful results in clinical trials: In the head-to-head SURMOUNT-5 trial, researchers reported injectable tirzepatide had a mean weight reduction of about 20.2% at 72 weeks, compared with roughly 13.7% for injectable semaglutide

Combination treatment with metformin does not confer additional benefits apart from a partial mitigation of weight gain due to rosiglitazone [48]

Injectable GLP-1 drugs were initially developed to treat diabetes, then approved for obesity